Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
Posted
March 28, 2024
Views
6,188
Likes
68
Comments
15
Engagement
March 28, 2024
6,188
68
15
1.34%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
5:53Now PlayingMerck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs.
For more on this story, please see
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
